Zhongzhu Healthcare Holding Co.,Ltd (SHA:600568)
1.990
-0.010 (-0.50%)
Nov 13, 2026, 3:00 PM CST
SHA:600568 Revenue
Zhongzhu Healthcare Holding Co.,Ltd had revenue of 132.02M CNY in the quarter ending September 30, 2026, with 1.34% growth. This brings the company's total for the last twelve months to 535.62M, down -6.13% year-over-year. In the year 2025, Zhongzhu Healthcare Holding Co.,Ltd had annual revenue of 577.34M with 10.73% growth. That makes Zhongzhu Healthcare Holding Co.,Ltd the 24,415th largest company in the world by revenue and 4,375th in China.
Revenue (ttm)
535.62M
Revenue Growth
-6.13%
P/S Ratio
7.17
Revenue / Employee
453.53K
Employees
1,181
Market Cap
3.84B
Revenue by Segment
- Medical Division 396.10M 67.2%
- Property development division 125.57M 21.3%
- Pharmaceutical and others 62.51M 10.6%
- Financial Leasing Division 5.38M 0.9%
Fiscal year ended Dec 31, 2025 See the full SHA:600568 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 577.34M | 55.96M | 10.73% |
| Dec 31, 2024 | 521.39M | -117.18M | -18.35% |
| Dec 31, 2023 | 638.56M | 132.59M | 26.21% |
| Dec 31, 2022 | 505.97M | -75.09M | -12.92% |
| Dec 31, 2021 | 581.06M | -146.41M | -20.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jinling Pharmaceutical Company | 3.17B |
| Jiangsu Lianhuan Pharmaceutical | 2.96B |
| Nanjing Well Pharmaceutical Group | 1.40B |
| Tianjin Lisheng Pharmaceutical | 1.27B |
| Hunan Hansen Pharmaceutical | 1.01B |
| LanZhou Foci Pharmaceutical | 941.70M |
| Nanjing Hicin Pharmaceutical | 814.80M |
| Lionco Pharmaceutical Group | 400.80M |